Alger Associates, Inc. Reports 10.2% Stake in Forte Biosciences, Inc. (FBRX)

Alger Associates, Inc. filed a Schedule 13G/A on May 15, 2026, disclosing a significant increase in its position in Forte Biosciences, Inc. (FBRX). As of the event date of March 31, 2026, the filer reported beneficial ownership of 1,272,596 shares of common stock, representing a 10.2% ownership stake in the company. This marks a substantial increase from the previously reported 0.0% position. The shares are held by open-end investment companies and managed accounts under Fred Alger Management, LLC (FAM), which is a subsidiary of Alger Group Holdings, LLC, which in turn is a subsidiary of Alger Associates, Inc. The filing indicates that the securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. The reporting person holds sole voting power over 1,268,303 shares and sole dispositive power over the full 1,272,596 shares. This amendment (No. 8) solidifies Alger Associates' position as a major institutional shareholder in the Dallas-based biotechnology firm.